UGT1A1*28 is a genetic variant that affects how your body metabolizes irinotecan, a chemotherapy drug used to treat colorectal, pancreatic, and other cancers. This variant reduces the activity of the UGT1A1 enzyme by approximately 70%, leading to slower drug clearance and increased risk of severe toxicity. Understanding your UGT1A1 status before starting irinotecan therapy can prevent life-threatening side effects and optimize treatment outcomes.
This guide explains the UGT1A1*28 variant, how it impacts irinotecan metabolism, FDA-approved dosing protocols, toxicity management strategies, and when genetic testing is essential. You'll learn practical steps to work with your oncology team for personalized chemotherapy dosing based on your genetic profile.
Understanding UGT1A1*28: The TA Repeat Polymorphism
The UGT1A128 variant involves an extra TA repeat in the TATA box promoter region of the UGT1A1 gene. Normal individuals have 6 TA repeats (UGT1A11), while those with UGT1A1*28 have 7 TA repeats. This seemingly small change significantly reduces enzyme expression in the liver.
How UGT1A1 Enzyme Works
UGT1A1 (UDP-glucuronosyltransferase 1A1) is responsible for converting toxic SN-38—the active metabolite of irinotecan—into an inactive, water-soluble compound that can be excreted. When enzyme activity is reduced, SN-38 accumulates in the bloodstream, exposing tissues to prolonged drug exposure.
Individuals with two copies of UGT1A1*28 (homozygous 7/7) metabolize irinotecan 30-50% slower than those with normal variants. Heterozygous individuals (6/7) show intermediate enzyme activity. The FDA recognizes this variant as clinically significant, requiring dose adjustments for safe irinotecan use.
Prevalence by Ancestry
| Population | UGT1A1*28 Frequency |
|---|---|
| European | 30-40% heterozygous, 10-15% homozygous |
| African | 35-45% heterozygous, 15-20% homozygous |
| Asian | 10-20% heterozygous, 2-5% homozygous |
| Hispanic | 25-35% heterozygous, 8-12% homozygous |
Approximately 10-15% of cancer patients carry two copies of UGT1A1*28, putting them at high risk for severe neutropenia and diarrhea without dose reduction.
Irinotecan Toxicity Risks with UGT1A1*28
Irinotecan is converted by carboxylesterase enzymes into SN-38, which is 100-1000 times more potent than the parent drug. SN-38 causes DNA damage in rapidly dividing cells, including both cancer cells and healthy bone marrow and intestinal cells.
Dose-Limiting Toxicities
Patients with reduced UGT1A1 activity experience three major toxicities:
-
Severe Neutropenia: Homozygous UGT1A1*28 carriers have 3-5 times higher risk of grade 3/4 neutropenia (absolute neutrophil count <1,000/μL). This can lead to life-threatening infections requiring hospitalization and antibiotics.
-
Severe Diarrhea: Delayed diarrhea occurs 24-72 hours after infusion due to SN-38 accumulation in intestinal cells. Homozygous patients experience grade 3/4 diarrhea in 30-50% of cycles versus 10-15% in normal metabolizers.
-
Mucositis and Fatigue: Prolonged SN-38 exposure damages rapidly dividing mucosal cells, causing painful mouth sores and overwhelming fatigue that can delay subsequent treatment cycles.
FDA Black Box Warning
The FDA label for irinotecan (Camptosar) includes a black box warning about UGT1A1*28. It states that patients homozygous for the *28 allele are at increased risk for neutropenia and should consider dose reduction, especially when starting at 125 mg/m² or higher doses.
After starting irinotecan, patients need close monitoring with the Ask My DNA app. Ask your DNA about chemotherapy drug metabolism to understand which UGT1A1 variants and other pharmacogenes affect your cancer treatment safety.
FDA-Approved Dosing Protocols for UGT1A1*28 Carriers
The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides evidence-based dosing guidelines for irinotecan based on UGT1A1 genotype. These recommendations balance efficacy and toxicity risk.
Standard vs. Reduced Dosing
| Genotype | Enzyme Activity | Starting Dose Recommendation | Monitoring Intensity |
|---|---|---|---|
| *1/*1 (6/6) | Normal | Standard dose (125-180 mg/m²) | Standard monitoring |
| *1/*28 (6/7) | Intermediate | Standard dose with close monitoring | Enhanced CBC monitoring |
| *28/*28 (7/7) | Reduced (30% activity) | Reduce dose by 30-50% | Intensive monitoring + prophylaxis |
For homozygous UGT1A1*28 patients starting on high-dose irinotecan (≥180 mg/m²), initial dose reduction to 100-120 mg/m² is recommended. For moderate-dose regimens (125 mg/m²), reduction to 80-100 mg/m² may prevent severe toxicity while maintaining therapeutic benefit.
Dose Escalation Strategy
If a reduced starting dose is well-tolerated for 2-3 cycles without grade ≥2 toxicity:
- Increase dose by 10-20 mg/m² for next cycle
- Monitor CBC before each cycle and on day 10-14
- Continue escalation until therapeutic dose or grade 2 toxicity occurs
- Maximum dose for homozygous patients: typically 70-80% of standard dose
This approach allows personalized dose optimization while minimizing early severe toxicity that could lead to treatment discontinuation.
Alternative Regimens
For patients who cannot tolerate dose-reduced irinotecan:
- FOLFOX: Oxaliplatin-based chemotherapy without irinotecan (no UGT1A1 interaction)
- Raltitrexed + Oxaliplatin: Available in some countries as irinotecan-free option
- Extended Infusion: 48-hour continuous infusion reduces peak SN-38 levels but requires central line
Managing Toxicity: Monitoring and Supportive Care
Even with dose reduction, UGT1A1*28 carriers require proactive monitoring and supportive care to maintain treatment adherence.
Pre-Cycle Laboratory Testing
Before each irinotecan cycle:
- Complete Blood Count (CBC): ANC must be ≥1,500/μL to proceed with treatment
- Liver Function Tests: Elevated bilirubin (>1.5x ULN) further impairs UGT1A1 activity
- Renal Function: Creatinine clearance <60 mL/min may require additional dose reduction
For homozygous patients, mid-cycle CBC on day 10-14 identifies early neutropenia, allowing prophylactic G-CSF (filgrastim) before infection develops.
Neutropenia Management
| Neutrophil Count | Action |
|---|---|
| 1,000-1,500/μL | Delay cycle 1 week, recheck CBC |
| 500-1,000/μL | Delay cycle, consider G-CSF support |
| <500/μL | Hospitalize if febrile, broad-spectrum antibiotics, G-CSF |
Prophylactic G-CSF starting 24-48 hours after irinotecan can reduce neutropenia risk by 50-70% in high-risk patients. Primary prophylaxis is recommended for homozygous UGT1A1*28 carriers on standard-dose regimens.
Diarrhea Management Protocol
Delayed diarrhea from irinotecan requires aggressive management:
- Immediate Response: High-dose loperamide (4 mg initial, then 2 mg every 2 hours until 12 hours diarrhea-free)
- Grade 3/4 Diarrhea: Hospitalization for IV fluids, electrolyte replacement, octreotide 100-150 μg subcutaneous three times daily
- Prophylaxis: Oral budesonide 9 mg daily may reduce diarrhea incidence in UGT1A1*28 homozygotes
Patients should maintain strict intake/output records and seek emergency care for >6 stools/day above baseline or signs of dehydration.
Genetic Testing Recommendations and Clinical Implementation
UGT1A1*28 testing is recommended before initiating irinotecan-based chemotherapy, especially for regimens using doses ≥125 mg/m².
Who Should Be Tested
- All patients starting irinotecan for colorectal cancer
- Pancreatic cancer patients receiving FOLFIRINOX (high-dose irinotecan component)
- Patients with prior severe toxicity on standard irinotecan dosing
- Individuals with family history of chemotherapy intolerance
Testing identifies not only UGT1A128 but also other reduced-function variants like UGT1A16 (common in Asian populations), which have similar clinical implications.
Genetic Testing Methods
| Method | Detects | Turnaround Time | Typical Cost |
|---|---|---|---|
| PCR-based assay | UGT1A1*28 only | 1-3 days | $200-400 |
| Sanger sequencing | *28, *6, and other variants | 5-7 days | $300-600 |
| Pharmacogenetic panel | UGT1A1 + 10-20 drug metabolism genes | 1-2 weeks | $400-1,000 |
Many insurance plans cover UGT1A1 testing when prescribed for irinotecan therapy planning. Medicare typically reimburses testing under code 81350.
Implementing Results in Clinical Practice
Once genotype is known:
- Document UGT1A1 status in electronic medical record with pharmacogenomics alert
- Calculate adjusted dose based on genotype and standard protocol
- Discuss rationale with patient, emphasizing that reduced dose maintains efficacy while improving safety
- Order prophylactic G-CSF and anti-diarrheal prescriptions before first cycle
- Schedule mid-cycle CBC for homozygous patients
Pharmacogenomic consultation services can help oncology teams interpret complex genotype results and recommend optimal dosing strategies.
Frequently Asked Questions
Will reducing my irinotecan dose make my cancer treatment less effective?
No. Studies show that dose reductions of 25-30% in UGT1A1*28 homozygous patients maintain therapeutic SN-38 exposure levels comparable to standard-dose treatment in normal metabolizers. The goal is to achieve the same drug exposure with lower administered dose, preventing severe toxicity that could force treatment delays or discontinuation. Treatment delays from toxicity are more likely to compromise outcomes than appropriately reduced starting doses.
If I've already had severe toxicity on irinotecan, is it too late to get genetic testing?
It's not too late, and testing can still provide valuable information. If you test positive for UGT1A1*28, this confirms the cause of your toxicity and justifies dose reduction for future cycles. It also alerts your medical team to avoid other drugs metabolized by UGT1A1, such as belinostat and nilotinib. Additionally, your family members may benefit from knowing about this variant if they ever need chemotherapy.
Can I take supplements or foods to increase my UGT1A1 enzyme activity?
There is no evidence that dietary supplements can meaningfully increase UGT1A1 expression in individuals with the *28/28 genotype. Cruciferous vegetables (broccoli, cauliflower) contain compounds that induce some UGT enzymes, but effects on UGT1A128 are minimal. Focus on medical management strategies: appropriate dose reduction, prophylactic supportive care, and close monitoring. Avoid St. John's Wort and other supplements that may interfere with chemotherapy effectiveness.
Does the UGT1A1*28 variant affect other cancer drugs besides irinotecan?
Yes. UGT1A1 also metabolizes other anticancer agents including belinostat (histone deacetylase inhibitor), nilotinib (tyrosine kinase inhibitor), and pazopanib. Patients with UGT1A1*28 may require dose adjustments or enhanced monitoring when using these drugs as well. Additionally, UGT1A1 metabolizes bilirubin; some *28/*28 individuals have mild Gilbert syndrome with slightly elevated unconjugated bilirubin, which is benign but can cause false alarm if not recognized.
📋 Educational Content Disclaimer
This article provides educational information about genetic variants and is not intended as medical advice. Always consult qualified healthcare providers for personalized medical guidance. Genetic information should be interpreted alongside medical history and professional assessment.